Slides
Page 1
Q3 2026 conference call and webcast Bad Homburg, 4 November 2026 Scaling the Growth Vectors, Core EPS Guidance improved © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026
Page 2
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward -looking statements contained in this presentation. cc At constant currency Core EPS Earnings per share excluding Fresenius Medical Care and Vitrea Core net income Net income excluding Fresenius Medical Care and Vitrea Safe harbor statement Glossary © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 20262
Page 3
01 Strategy and Business Update 01 Strategy and Business Update 02 Financials 02 Financials 03 #FutureFresenius 03 #FutureFresenius 04 Appendix 04 Appendix © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 20263
Page 4
Q3/26: Core EPS Guidance improved © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Healthy organic growth: Across Fresenius Kabi and Fresenius Helios +5% Q3/26 Organic Growth Raising FY/26 Group margin indication: Strong profitability despite usual seasonality 11.0% Q3/26 Group EBIT margin Return focus pays off: ROIC reaching mid- point of the ambition range 7.0% Q3/26 ROIC Substantially improved Cash Flow: Free Cash Flow more than doubled year-on- year 1.9bn Q3/26 LTM Free Cash Flow Excellent bottom-line: Consistent delivery at upper end of the upgraded Guidance range +14% Q3/26 Core EPS growth cc Before special items 4 FY/26 Guidance Improved Core EPS growth cc in the upper half of the 10 – 15% range
Page 5
Fresenius Kabi: Q3/26 news Biopharma Expanding U.S. direct-to-payer- access: New agreement with Waltz Health €296m Brazilian Health Regulatory Agency (Anvisa) approves Tyenne tech transfer to Garin, ARG Q3/26 revenue +29% Organic growth Nutrition Advancing innovation agenda: • NutriChef® launch • Addition of Fresubin® PRO COMPACT and PRO CRÈME €646m Mandatory nutrition- screening standards expected to be intro- duced by end of 2027 in Germany Q3/26 revenue +4% Organic growth MedTech Ivenix momentum further accelerated: • Contract secured with large multi-hospital system in U.S. (AZ) • >30k total installed base €428m Q3/26 revenue +6% Organic growth Pharma Expanding European production capacity for IV fluids: New product lines in Kutno, Poland and Isola della Scala, Italy €935m U.S. launches: Sugammadex pre-filled syringe and Nicardipine premix bag Q3/26 revenue +1% Organic growth © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Organic growth rates adjusted for accounting effects related to Argentina hyperinflation 5
Page 6
Tyenne • 45% volume increase in Q3/26 (YOY) • Additional supply secured to address strong demand in growing market Bomyntra & Conexxence • Strong uptake continues • #1 or #2 in several key European markets • Product diversification with pre-filled syringe (oncology) a key growth driver EU5: 39% U.S.: 20% © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 20266 Fresenius Kabi: Biopharma growth engine Q1/25 Q2/25 Q3/25 Q4/25 Q1/26 Q2/26 EU5: 1% U.S.: 4% Aug/26 Source: IQVIA Market shares, by molecule EU5: 12% U.S.: 8%
Page 7
Rigorous execution on quality management and process enhancements is part of the ReJuvenate agenda Digitalization & AI initiatives: • Automatization, improved visibility and access to information • Streamlined batch release • Standardized, audit-proof workflows across global network • Early risk-detection and trend analysis Melrose Park: A specific and manageable self-help opportunity • Facility remains fully operational: No material impact on production, supply, or FY/26 financial performance expected • No patient safety concerns • Leveraging broad U.S. network • Mitigation measures already underway in close collaboration with FDA © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 20267 Fresenius Kabi: Quality firmly embedded across all operations
Page 8
Fresenius Helios: Q3/26 news Spain Peer-reviewed research confirms benefits of “Scribe”: • Ambient AI reduces documentation burden while maintaining quality • Used in >10 million consultations to date €1,307m Q3/26 revenue +5% Organic growth © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 8 Germany €2,099m Q3/26 revenue +5% Organic growth Constructive reimburse- ment environment in FY/27: • DRG inflator at 4.85%1 • €450m surcharge for all non- university hospitals introdu- ced into legislative process Planned NVIDIA investment a strong validation for FRE- backed Avelios Medical Before special items 1 Expected 2027 DRG inflator: 3.42% base wage rate (net of 1pp GKV Stabilization Act deduction, 2027 –2029) + 0.29% tariff rate compensation + 1.14% one -time base adjustment = 4.85%
Page 9
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 20269 Building a vertically-integrated Bio powerhouse 100% ownership in mAbxience Full control over scalable, cost- competitive development and manufacturing platform: • 2× 24kl bioreactor cell culture capacity • 400l bacteria fermentation capacity • Single-use technology Top3 Market position by 2035 Ambition to achieve 1 Originator list-price-based sales WuXi Biologics exclusive development agreement • Option rights for up to 37 potential first-to-market candidates • Opportunity to expand next- generation portfolio to 66 molecules across 13 therapeutic areas, addressing >€370b in originator sales1 • First launch opportunities expected in early 2030s
Page 10
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202610 Scaling the Growth Vectors for innovation-led growth 9.3% 33% 67% FY/23 45% 55% FY/24 48% 52% FY/25 17.3% 55% 45% Q1-3/26 Growth Vectors margin1 Growth Vectors1 Pharma Fresenius Kabi EBIT Before special items; excl. Corporate 1 Nutrition, MedTech & Biopharma 2 Products launched in Q4/23 or thereafter ~€850m Q3/26 LTM Revenue from new products2 30% of Group EBIT
Page 11
01 Strategy and Business Update 01 Strategy and Business Update 02 Financials 02 Financials 03 #FutureFresenius 03 #FutureFresenius 04 Appendix 04 Appendix © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202611
Page 12
Q3/26: Excellent EPS growth fueled by strong operating performance Organic Revenue growth of 5%, driven by both Fresenius Kabi and Fresenius Helios EBIT margin of 11.0% (+50bps YOY; Q1-3/26: 11.7%) despite usual seasonality at Helios Excellent Core EPS growth of 14%, largely driven by strong operating performance Interest expense decreased to -€75m YOY (Q3/25: -€81m) Tax rate at 25.5% (Q3/25: 24.7%), in line with expectations for FY/26 (Q1-3/26: 24.5%) Strong Operating Cash Flow, driven by both Fresenius Kabi and Fresenius Helios Leverage ratio at 2.5×, including acquisition of remaining mAbxience stake Special items Q3/26 (EAT): €54m (excl. €61m FMC & Vitrea) Before special items | 1 Organic growth rates adjusted for ARG hyperinflation | 2 From continuing operations | 3 Excl. FMC & Vitrea; at average exchange rates for both Net debt and EBITDA; before special items; pro forma closed acquisitions/divestitures, including lease liabilities, including dividends from Fresenius Medical Care & Vitrea; Net debt adjusted for valuation effect of exchangeable bond €5.8bn +5%1 org. Revenue €638m +10% cc EBIT 11.0% +50bps EBIT margin €0.72 +14% cc Core EPS €633m Operating Cash Flow2 2.5× Net Debt / EBITDA3 © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202612
Page 13
Organic revenue growth1 2,141 2,214 2,150 2,244 16.7% 7% Q3/25 15.8% 10% Q4/25 16.7% 6% Q1/26 17.0% 7% Q2/26 17.0% Q3/26 6% Fresenius Kabi Q3/26 financials Consistent Organic Revenue growth of 6%, in the upper half of the structural growth band (4 – 7%) • Growth Vectors with strong 9%1 Organic growth (Biopharma: 29%1; MedTech: 6%1; Nutrition: 4%1) • Pharma with organic growth of 1%1; strong I.V. Solutions business and U.S. volumes partially offset by U.S. price developments Excellent EBIT margin of 17.0% and strong EBIT growth (cc) of 8% Growth Vectors margin at 18.3% (+240bps YOY), once again within the structural margin band (17 – 19%); Biopharma further improved – at the level of 2030 margin ambition Pharma margin at 20.0%; 20.1% YTD margin well in line with FY/26 expectations Before special items 1 Organic growth rates adjusted for accounting effects related to Argentina hyperinflation 358 349 EBIT €m Revenue €m EBIT margin 358 © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 382 13 391 2,304
Page 14
3,240 3,546 3,526 3,405 7.5% 5% Q3/25 11.7% 8% Q4/25 10.5% 4% 3,501 Q1/26 10.6% 5% Q2/26 8.6% 5% Q3/26 Fresenius Helios Q3/26 financials Strong Organic Revenue growth of 5%, in line with structural growth band (4 – 6%) Excellent EBIT margin of 8.6% (+110bp YOY), reflecting usual seasonality at Helios Spain Helios Germany: • Strong 5% organic revenue growth, driven by positive pricing and solid volume growth • Outstanding EBIT growth (cc) of 25% and +160bps EBIT margin expansion YOY, incl. surcharge for publicly insured patients and supported by continued cost management focus Helios Spain: • Strong 5% organic revenue growth, driven by positive pricing as well as strong performance in Spain; reduced activity levels in Colombian hospitals • Good EBIT growth (cc) of 10% driven by operating leverage; 7.0% (+40bps YOY) margin reflecting usual seasonality Before special items 242 416 Organic revenue growth EBIT €m Revenue €m EBIT margin 368 © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 374 14 293
Page 15
131 656 Q3/26 LTM Operating Cash Flow -781 CAPEX, net -619 Dividends paid Dividends received Acquisitions, net -202 Leases Q3/26 LTM Free Cash Flow1 2,700 1,885 Free Cash Flow more than doubled year-on-year From continuing operations | Q3/26 LTM Free Cash Flow from discontinued operations amounted to -€187m, mainly due to disposals from the VIACAMA exit 1 After acquisitions, dividends and lease liabilities | 2 Cash conversion rate – defined as adjusted FCFbIT / EBIT (before special items) Strong Operating Cash Flow and cash conversion: Q3/26 LTM CCR2: 1.1 FY/25 CCR2: 1.1 FY/24 CCR2: 1.1 FY/23 CCR2: 1.0 ~€640m FME proceeds: • ~€330m from LTM pro- rata sale alongside FME share buyback • ~€310m from share sale in Aug. 2026 Cash Flow, €m incl. proceeds from FME share sales incl. -€27m minority interest © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 911 Q3/25 LTM Free Cash Flow1 15 ~€720m cash outflow from mAbxience acquisition in Cash Flow from Financing Activities
Page 16
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202616 Biopharma transactions: Retaining strategic control, flexibility and economic ownership We allocate capital to most compelling opportunities We maintain strategic flexibility Potential to triple portfolio without upfront capital commitment Full flexibility in selecting and advancing development programs Retaining full commercialization economics Committed to a strong Balance Sheet No significant Leverage effect and no implication for self-imposed target corridor (2.5 – 3.0×)
Page 17
Organic revenue growth 4 – 7% Core EPS growth cc 10 – 15% Expected in upper half of the range Before special items Guidance assumes current factors and known uncertainties but does not reflect potential extreme scenarios from a fast-moving geopolitical environment. Indications Fresenius Group EBIT margin above 11.5% (previously: around 11.5%) FY/25 base: €2,595m Fresenius Kabi Mid- to high-single-digit org. revenue growth FY/25 base: €8,612m EBIT margin at the upper end of the 16.5 – 17.0% range Structural EBIT margin band of 17 – 19% | FY/25 base: €1,413m Fresenius Helios Mid-single-digit organic revenue growth FY/25 base: €13,550m EBIT margin of 10.0 – 10.5% Structural EBIT margin band of 10 – 12% | FY/25 base: €1,328m Core EPS growth expected in upper half of Guidance range, raising Group EBIT margin indication © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202617
Page 18
01 Strategy and Business Update 01 Strategy and Business Update 02 Financials 02 Financials 03 #FutureFresenius 03 #FutureFresenius 04 Appendix 04 Appendix © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202618
Page 19
REJUVENATE in action Before special items 1 Growth rates adjusted for ARG hyperinflation Structural step-up #FutureFresenius translating into continued earnings strength Scaling growth platforms Leveraging strategic flexibility in executing the next stage of the ReJuvenate agenda Seizing opportunities Converting strong operational momentum into innovation-led growth Sustainable value creation Deploying capital with discipline and return focus Q1-3/26 FY/251 EBIT margin 11.7% 11.5% Core EPS growth cc +14% +12% © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Sustainable value creation: 7.0% Q3/26 ROIC (13.8% excl. Goodwill) 19
Page 20
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202620 10 December 2026 Meet the Management Nutrition Virtual event
Page 21
01 Strategy and Business Update 01 Strategy and Business Update 02 Financials 02 Financials 03 #FutureFresenius 03 #FutureFresenius 04 Appendix 04 Appendix © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202621
Page 22
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202622 Fresenius Group Capital allocation priorities Profitable Growth Disciplined CAPEX – focus on investments in organic growth Value-enhancing business development Attractive shareholder returns Distribution of 30 – 40% of Core net income1 in line with dividend policy Excess cash returns if appropriate and aligned with strategy Strong balance sheet Leverage within self-imposed target corridor of 2.5 – 3.0× Strong commitment to Investment Grade rating 1 Before special items
Page 23
Ambitions geared for substantial earnings growth Strong balance across growth and stable cash flow Committed to strong balance sheet © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Fresenius Financial Framework All figures before special items 1 Cash conversion rate – defined as adjusted FCFbIT / EBIT (before special items) EBIT margin 10 – 12%17 – 19% Organic revenue growth 4 – 6%4 – 7% Capital Efficiency ROIC 6 – 8% Capital Structure Leverage ratio 2.5 – 3.0x Cash CCR1 ~1 Dividend policy Pay out 30 – 40% of Core net income Fresenius Kabi Fresenius Helios 23
Page 24
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group FY/26 indications Before special items 1 Adjusted for proceeds from sale of St. Wendel and Schweinfurt production sites used by Fresenius Medical Care €m FY/25 FY/26 indication Operating Companies Fresenius Kabi Organic revenue growth EBIT margin 7% 16.4% Mid- to high-single-digit At the upper end of the 16.5 – 17.0% range Fresenius Helios Organic revenue growth EBIT margin 7% 9.8% Mid-single-digit 10.0 – 10.5% Profitability Group EBIT margin 11.5% Above 11.5% Interest expense €324m Below €300m Tax rate 25.6% 24 – 25% Capital Allocation CAPEX (% of revenue) 4.4%1 Around 5.5% CCR LTM 1.1 Slightly below 1 ROIC 6.6% Above 6.5% Leverage ratio 2.7x Within the target corridor of 2.5 – 3.0x Net debt/EBITDA 24
Page 25
Macroeconomic environment: Geopolitical conflicts, i.e. Middle East Exchange rate fluctuation Supply chain complexity Global regulation U.S. tariffs © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group FY/26 indications 1 Alpha Ketoanalogues of essential amino acids for treatment of patients with Chronic Kidney Disease Q4/26 effects Kabi: Consistent topline growth Kabi: Annualization of Ketosteril®1 Volume-based Procurement impact in China Helios: GER surcharge (Nov. 2025 – Oct. 2026) Ramp-up of targeted investments: e.g. pipeline & portfolio, production capabilities, digital backbone, R&D Helios: High prior-year base due to strong Q4/25 performance LTIP: potential catch-up effects 25
Page 26
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Currency sensitivities & exposure Growth sensitivities Currency Variation Revenue EBIT Core EPS U.S. Dollar (USD) +1 Cent EURUSD ~-10bps ~-25bps ~-25bps Argentine Peso (ARS) +100 Pesos EURARS ~-5bps ~-10bps ~-10bps Currency FY/25 EUR/USD 1.13 EUR/ARS 1,416 Currency average rates (base rates) 71% 11% 3% 14% EUR USD CNY ARS 1% Other Currency exposure FY/25 Revenue FY/26 currency sensitivities 26
Page 27
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group: Business overview Driving growth, accelerating performance Strong underlying, sustained leadership BiopharmaGermany Pharma Nutrition MedTech 2026 PERFORMANCE DRIVERS: tocilizumab ustekinumab roll-out denosumab roll-out Volume & price Core & support processes Clustering Pipeline delivery Wilson ramp-up More in America Cost & efficiency Enteral volume Launches & roll-outs Wuxi ramp-up Ivenix Nomogram Cost & efficiency Volume & price Process efficiency, digitally enabled Occupational health WHERE WE ARE HEADED: Vertically- integrated Bio powerhouse Clear market leader Global IV Gx & Fluids leader Leader in integrated nutrition Scaled MedTech platform Clear market leader2 Spain REVENUE1: 4–6% p.a. organic growth 2–4% p.a. organic growth 4–7% p.a. organic growth 8–10% p.a. organic growth 4–6% p.a. organic growth Earnings growth ≥ revenue growth Stable margin performance and growing earnings Stable margins at high level with upside Strong margin improvement Earnings growth ≥ revenue growthPROFITABILITY1: ~2× revenue3 by 2030 ~20% margin4 by 2030 Fresenius Helios Fresenius Kabi 1 As stated at respective Capital Markets Day | 2 Relates to private hospital market in Spain | 3 Basis: FY/25 revenue of €871m | 4 Based on certain pipeline, portfolio, pricing, and market share assumptions 27
Page 28
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Q3/26 Statement of income (Summary, IFRS, unaudited) After Special Items | 1 Prior-year figures have been adjusted due to the re-presentation of the remaining parts of Vamed’s Austrian activities under continued operations. | 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA €m Q3/26 Q3/25 restated1 Q3/25 previous Growth Revenue 5,884 5,556 5,485 6% Costs of revenue -4,351 -4,252 -4,185 -2% Gross profit 1,533 1,304 1,300 18% Selling, general and administrative expenses -823 -679 -676 -21% Research and development expenses -169 -159 -159 -6% Other operating result 33 1 1 – Operating income (EBIT) 575 467 466 23% Income from investments accounted for using the equity method 22 66 66 -67% Interest result -79 -81 -81 3% Other financial result 8 28 28 -72% Income before income taxes 526 480 479 10% Income taxes -139 -117 -116 -18% Net income from continuing operations 387 363 363 7% Noncontrolling interests in continuing operations 16 20 20 -19% Net income from continuing operations2 371 343 343 8% Net income from discontinued operations 2 – 1 1 – Net income 387 364 364 6% Noncontrolling interests in net income 16 20 20 -19% Net income2 371 344 344 8% Earnings per ordinary share (€) 0.66 0.62 0.62 8% 28
Page 29
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Q1-3/26 Statement of income (Summary, IFRS, unaudited) After Special Items | 1 Prior-year figures have been adjusted due to the re-presentation of the remaining parts of Vamed’s Austrian activities under continued operations. | 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA €m Q1-3/26 Q1-3/25 restated1 Q1-3/25 previous Growth Revenue 17,648 16,912 16,717 4% Costs of revenue -13,030 -12,733 -12,548 -2% Gross profit 4,618 4,179 4,169 10% Selling, general and administrative expenses -2,326 -2,064 -2,059 -13% Research and development expenses -499 -463 -463 -8% Other operating result 16 66 66 -76% Operating income (EBIT) 1,808 1,718 1,713 5% Income from investments accounted for using the equity method 37 122 122 -69% Interest result -221 -247 -248 11% Other financial result 13 -6 -6 – Income before income taxes 1,637 1,587 1,581 3% Income taxes -407 -405 -402 0% Net income from continuing operations 1,231 1,182 1,179 4% Noncontrolling interests in continuing operations 41 48 48 -14% Net income from continuing operations2 1,189 1,134 1,131 5% Net income from discontinued operations 2 -1 -231 -228 100% Net income 1,230 951 951 29% Noncontrolling interests in net income 41 48 48 -14% Net income2 1,188 903 903 32% Earnings per ordinary share (€) 2.11 1.61 1.61 32% 29
Page 30
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Q3/26 Reconciliation 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA 30 €m Q3/26 Q3/25 Growth rate Growth rate at cc Revenue reported (after special items) 5,884 5,556 6% 4% Legacy portfolio adjustments -9 - Fresenius transformation -73 -79 Revenue (before special items) 5,803 5,477 6% 4% EBIT reported (after special items) 575 467 23% 21% Cost and efficiency programs 37 43 Legacy portfolio adjustments 15 9 Fresenius transformation 47 49 Reduction of participation in Fresenius Medical Care -37 -4 Legal and regulatory matters 2 10 EBIT (before special items) 638 574 11% 10% Net income reported (after special items)1 371 344 8% 7% Cost and efficiency programs 27 36 Legacy portfolio adjustments 14 8 Fresenius transformation 50 53 Reduction of participation in Fresenius Medical Care -38 -31 Legal and regulatory matters 1 7 Special items Fresenius Medical Care 61 44 Net income (before special items)1 486 461 5% 5%
Page 31
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Q1-3/26 Reconciliation 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA 31 €m Q1-3/26 Q1-3/25 Growth rate Growth rate at cc Revenue reported (after special items) 17,648 16,912 4% 4% Legacy portfolio adjustments -19 -1 Fresenius transformation -219 -232 Revenue (before special items) 17,411 16,679 4% 4% EBIT reported (after special items) 1,808 1,718 5% 6% Cost and efficiency programs 83 96 Legacy portfolio adjustments 53 20 Fresenius transformation 126 114 Reduction of participation in Fresenius Medical Care -44 -76 Legal and regulatory matters 9 10 EBIT (before special items) 2,035 1,882 8% 9% Net income reported (after special items)1 1,188 903 32% 33% Cost and efficiency programs 62 79 Legacy portfolio adjustments 50 17 Fresenius transformation 116 358 Reduction of participation in Fresenius Medical Care -52 -63 Legal and regulatory matters 6 7 Special items Fresenius Medical Care 233 142 Net income (before special items)1 1,604 1,443 11% 12%
Page 32
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Indicative presentation of future disclosure of operating profit in accordance with IFRS 18 IFRS 18 applied from 2027 onwards IFRS 18 amends a number of other standards and will replace IAS 1, Presentation of Financial Statements. IFRS 18 requires presenting the statement of pr ofit or loss in three newly defined categories (operating, investing and financing category). Accordingly, pension-related interests, income and loss from investments as well as gains and losses from financial investments and fair value measurements which are currently included in operating income (EBIT) will be presented in the investing or financing category. IFRS 18 will not affe ct the classification of net income from the investments in Fresenius Medical Care and Vitrea as it is already disclosed outside operating income (EBIT). Furthermore, interest expenses and income related to income taxes as well as fees and interests relating to factoring and val uation effects from the exchangeable bond will be included in the operating category instead of in interest income, interest expense or other financial result. Based on the analyses for the first nine months of 2026, the Fresenius Group expects an operating profit before special items calculated in accordance with IFRS 18 of €2,026 million for the first nine months of 2026. In comparison, EBIT before special items calculated in accordance with IAS1 amounts to €2,035 million. The difference results only from changes in presentation due to the new IFRS 18 categories. €m Q1-3/26 IAS 1 Q1-3/26 IFRS 18 (preview) EBIT (IAS 1) / operating profit (IFRS 18) – before special items 2,035 2,026 Deviation is mainly based on changes in presentation of: • Income from investments • Pension interest • Gains from financial investments & Fair value measurement & Dividends 32
Page 33
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Indicative comparison: EBIT before special items (IAS 1) vs. operating profit before special items (IFRS 18) €m (before special items) Q1/26 IAS 1 Q2/26 IAS 1 Q3/26 IAS 1 Q1-3/26 IAS 1 Revenue 5,744 5,864 5,803 17,411 Cost of Revenue -4,203 -4,305 -4,271 -12,779 Gross Profit 1,540 1,559 1,532 4,631 Selling general and administrative expenses -683 -683 -726 -2,092 Research and development expenses -163 -167 -169 -499 Other operating result -17 10 1 -6 Operating income (EBIT) 678 719 638 2,035 Income from investments accounted for using the equity method 98 90 83 271 Net interest -68 -72 -75 -215 Income before income taxes 708 737 646 2,091 €m (before special items) Q1/26 IFRS 18 Q2/26 IFRS 18 Q3/26 IFRS 18 Q1-3/26 IFRS 18 Revenue 5,743 5,863 5,802 17,409 Cost of Revenue -4,202 -4,304 -4,270 -12,776 Gross Profit 1,541 1,559 1,533 4,633 Selling, general and administrative expenses -679 -679 -721 -2,079 Research and development expenses -163 -167 -169 -498 Other operating result -27 2 -5 -30 Operating profit 673 715 638 2,026 Income from investments accounted for using the equity method 98 90 83 271 Other investing result 26 15 19 60 Income before financing and income taxes 797 819 741 2,357 Financing result -88 -83 -95 -266 Income before income taxes 708 737 646 2,091 Preliminary & unaudited 33
Page 34
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Q3/26 Revenue Revenue by region, % Revenue by business segment, % Before special items 34 73 13 7 6 1 Europe North America Asia-Pacific Latin America Africa €5.8bn 40 59 1 Fresenius Kabi Fresenius Helios Corporate/ Other €5.8bn
Page 35
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Fresenius Group Q1-3/26 Revenue Revenue by region, % Revenue by business segment, % Before special items 35 74 12 7 6 1 Europe North America Asia-Pacific Latin America Africa €17.4bn 38 60 2 Fresenius Kabi Fresenius Helios Corporate/ Other €17.4bn
Page 36
Fresenius Group Q3/26 Revenue growth by business segment 1 Before special items For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202636 €m Q3/26 Q3/25 Growth at actual rates Currency translation effects Growth at constant rates 1 Organic growth1 Acqui- sitions Divestitures /others % of total revenue Fresenius Kabi 2,304 2,141 8% 3% 5% 6% 0% -1% 40% Fresenius Helios 3,405 3,240 5% 1% 4% 5% 0% -1% 59% Corporate/Other 93 96 n/a n/a n/a n/a n/a n/a 1% Total 5,803 5,477 6% 2% 4% 5% 0% -1% 100%
Page 37
Fresenius Group Q1-3/26 Revenue growth by business segment 1 Before special items For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202637 €m Q1-3/26 Q1-3/25 Growth at actual rates Currency translation effects Growth at constant rates 1 Organic growth1 Acqui- sitions Divestitures /others % of total revenue Fresenius Kabi 6,699 6,398 5% -1% 6% 6% 0% 0% 38% Fresenius Helios 10,433 10,004 4% 0% 4% 5% 0% -1% 60% Corporate/Other 279 277 n/a n/a n/a n/a n/a n/a 2% Total 17,411 16,679 4% 0% 4% 5% 0% -1% 100%
Page 38
Fresenius Group Q3/26 Corporate Before special items 1 Fresenius Health Services: hospital services business, previously owned by Vamed © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202638 €m Q3/26 Q3/25 Corporate Revenue 93 96 thereof Corporate -68 -86 thereof FHS1 161 182 €m Q3/26 Q3/25 Corporate EBIT -45 -26 thereof Corporate -58 -40 thereof FHS1 13 14
Page 39
Fresenius Group Q1-3/26 Corporate Before special items 1 Fresenius Health Services: hospital services business, previously owned by Vamed © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202639 €m Q1-3/26 Q1-3/25 Corporate Revenue 279 277 thereof Corporate -219 -247 thereof FHS1 498 524 €m Q1-3/26 Q1-3/25 Corporate EBIT -130 -94 thereof Corporate -162 -123 thereof FHS1 32 29
Page 40
Fresenius Group Q3/26 Calculation of noncontrolling interests Before special items For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202640 €m Q3/26 Q3/25 Earnings before tax and noncontrolling interests 563 493 Taxes -143 -122 Noncontrolling interests, thereof -16 -20 Fresenius Kabi -15 -18 Fresenius Helios -1 -2 Corporate 0 0 Net income from Fresenius Medical Care and Vitrea 83 110 Net income attributable to Fresenius SE & Co. KGaA 486 461
Page 41
Fresenius Group Q1-3/26 Calculation of noncontrolling interests Before special items For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202641 €m Q1-3/26 Q1-3/25 Earnings before tax and noncontrolling interests 1,820 1,635 Taxes -446 -408 Noncontrolling interests, thereof -41 -48 Fresenius Kabi -34 -41 Fresenius Helios -7 -7 Corporate -1 0 Net income from Fresenius Medical Care and Vitrea 271 264 Net income attributable to Fresenius SE & Co. KGaA 1,604 1,443
Page 42
Fresenius Group Q3/26 & Q3/26 LTM Cash flow development Cash flow from continuing operations © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202642 €m Q3/26 Q3/25 Q3/26 Q3/25 LTM LTM OCF 633 758 2,694 2,260 thereof Kabi 462 443 1,400 1,158 thereof Helios 284 332 1,488 1,306 % OCF Margin 11% 13.8% 11.6% 10.2% Capex (net) -190 -234 -781 -973 Capex (net) in % of Revenue -3.3% -4.3% -3.4% -4.4% Dividends recieved from FME + Vitrea 0 0 131 121 Acquisition (net) 355 -15 656 364 Dividends paid (incl. minority interest) -27 -28 -619 -684 Lease liabilities -50 -47 -202 -177 FCF 722 434 1,880 911
Page 43
Fresenius Group Q3/26 & LTM Reconciliation: Adjusted Free Cash Flow for CCR Cash flow from continuing operations Q3/2026 LTM adjusted for proceeds from sale of St. Wendel and Schweinfurt production sites used by Fresenius Medical Care; ot herwise €781m net Capex © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202643 €m Q3/2026 Q3/2025 LTM LTM Operating Cash Flow 2,694 2,260 Capex -952 -973 Free Cash Flow (Before acquisitions, dividends, and lease liabilities) 1,742 1,287 Special items (net income before minorities) 410 290 Interests (before special items) 292 344 Taxes (before special items) 620 562 Adjusted Free Cash Flow for CCR 3,064 2,483
Page 44
Fresenius Group Q3/26 Cash flow development by business segment Cash flow from continuing operations 1 Before acquisitions, dividends and lease liabilities © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202644 Operating Cash Flow Capex Free Cash Flow1 €m Q3/26 Q3/25 Q3/26 Q3/25 Q3/26 Q3/25 Q3/26 Q3/25 Q3/26 Q3/25 Q3/26 Q3/25 Margin Margin % rev. % rev. Margin Margin Fresenius Kabi 462 443 20.1% 20.7% -100 -93 -4.3% -4.3% 362 350 15.7% 16.3% Fresenius Helios 284 332 8.3% 10.2% -87 -115 -2.5% -3.5% 197 217 5.8% 6.7% Corporate/Other -114 -17 -2 -26 -116 -43 Fresenius Group 633 758 10.9% 13.8% -189 -234 -3.3% -4.3% 444 524 7.6% 9.6%
Page 45
Fresenius Group Q3/26 LTM Cash flow development by business segment Cash flow from continuing operations 1 Corporate/Other Capex in Q3/26 LTM adjusted for proceeds from sale of St. Wendel and Schweinfurt production sites used by Fre senius Medical Care –otherwise €272m net Capex 2 Before acquisitions, dividends and lease liabilities © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202645 Operating Cash Flow Capex Free Cash Flow €m Q3/26 Q3/25 Q3/26 Q3/25 Q3/26 Q3/25 Q3/26 Q3/25 LTM LTM Q3/26 Q3/25 LTM LTM Q3/26 Q3/25 LTM LTM LTM LTM Margin Margin LTM LTM % rev. % rev. LTM LTM Margin Margin Fresenius Kabi 1,400 1,158 15.7% 13.6% -397 -416 -4.5% -4.9% 1,003 742 11.3% 8.7% Fresenius Helios 1,488 1,306 10.6% 9.8% -525 -487 -3.8% -3.7% 963 819 6.9% 6.2% Corporate/Other -194 -204 101 51 78 -153 Fresenius Group 2,694 2,260 11.6% 10.2% -821 -852 -3.5% -3.8% 2,044 1,408 8.8% 6.3%
Page 46
Fresenius Group Capital efficiency and returns 1 Prior-year figures have been adjusted due to the deconsolidation of Fresenius Medical Care operations l 2 LTM l 3 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including dividends from Fresenius Medical Care & Vitrea; Net debt adjusted for valuation effect of exchangeable bond © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 ROIC1, % CCR1,2 Net debt / EBITDA1,3 6.2 6.2 6.2 6.3 6.6 6.8 6.9 7.0 4.0 5.0 6.0 7.0 8.0 9.0 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 1.1 1.1 1.2 1.2 0.8 0.9 1.0 1.1 1.2 1.3 Q4 24 Q1 25 1.0 Q2 25 1.0 Q3 25 1.1 Q4 25 Q1 26 Q2 26 1.1 Q3 26 2.0 2.5 3.0 3.5 4.0 3.0 Q4 24 3.0 Q1 25 3.1 Q2 25 3.0 Q3 25 2.7 Q4 25 2.6 Q1 26 2.6 Q2 26 2.5 Q3 26 46
Page 47
Fresenius Kabi Q3/26 Organic revenue growth by product group 1 Consists of MedTech, Nutrition, Biopharma 2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202647 €m Q3/26 ΔYoY organic2 MedTech 428 6% Nutrition 646 4% Biopharma 296 29% Growth Vectors1 1,370 9% Pharma (IV Drugs & Fluids) 935 1% Corporate 0 0 Total revenue 2,304 6%
Page 48
Fresenius Kabi Q1-3/26 Organic revenue growth by product group 1 Consists of MedTech, Nutrition, Biopharma 2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202648 €m Q1-3/26 ΔYoY organic2 MedTech 1,256 7% Nutrition 1,869 4% Biopharma 793 33% Growth Vectors1 3,918 10% Pharma (IV Drugs & Fluids) 2,781 2% Corporate 0 0 Total revenue 6,699 6%
Page 49
Fresenius Kabi Q3/26 EBIT(DA) development All figures before special items Margin growth at actual rates 1 Consists of MedTech, Nutrition, Biopharma For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202649 ΔYoY cc€m Q3/26 Total EBITDA 520 5% Margin 22.6% -10 bps Total EBIT 391 8% Margin 17.0% +30 bps Growth Vectors1 251 27% Margin 18.3% +240 bps Pharma (IV Drugs & Fluids) 187 -10% Margin 20.0% -200 bps Corporate -47 --
Page 50
Fresenius Kabi Q1-3/26 EBIT(DA) development All figures before special items Margin growth at actual rates 1 Consists of MedTech, Nutrition, Biopharma For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202650 ΔYoY cc€m Q1-3/26 Total EBITDA 1,523 7% Margin 22.7% +20 bps Total EBIT 1,131 8% Margin 16.9% +30 bps Growth Vectors1 680 27% Margin 17.3% +210 bps Pharma (IV Drugs & Fluids) 558 -9% Margin 20.1% -210 bps Corporate -107 --
Page 51
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202651 Fresenius Kabi Global biosimilars portfolio and pipeline value molecules Molecules by stage of clinical development, peak branded originator sales (€bn)1 9 5 8 ~85 Marketed ~35 Approved / in registration / clinical / process validation ~93 Disclosed molecules in early-stage development ~157 Undisclosed molecules in early-stage development Total >370 aflibercept rituximab2 vedolizumab etanercept* nivolumab* dupilumab guselkumab risankizumab secukinumab teprotumumab3 polatuzumab vedotin3 emicizumab* durvalumab 44 adalimumab denosumab2 pegfilgrastim tocilizumab ustekinumab pembrolizumab* bevacizumab* denosumab2* rituximab2* 66 1 Originator peak sales based on internal analysis from multiple subscription databases. 2 Counted twice because both mAbxience and Fresenius have the molecule separately. 3 Part of Wuxi Biologics agreement. * Out-licensed molecule
Page 52
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202652 Fresenius Kabi Marketed biosimilars portfolio Launch1 Therapy Area Brand (Molecule) Reference Product Region Potential Revenue Contribution 2025 Oncology (Osteoporosis) Izamby/Denbrayce (denosumab)2 Prolia®/Xgeva® US, EU, RoW 2025 Oncology (Osteoporosis) Conexxence/Bomyntra (denosumab) Prolia®/Xgeva® US, EU, RoW 2025 Immunology Otulfi (ustekinumab) Stelara® US, EU, RoW 2024 Oncology Pembrox (pembrolizumab)2 Keytruda® RoW 2023 Immunology Tyenne (tocilizumab) Actemra®/ RoActemra® US, EU, RoW 2022 Oncology Stimufend (pegfilgrastim) Neulasta® US, EU 2019 Immunology Idacio (adalimumab) Humira® US, EU, RoW 2016 Oncology Alymsys (bevacizumab)2 Avastin® US, EU, RoW 2014 Oncology Novex (rituximab)2 MabThera®/Rituxan® RoW Limited Moderate High Note: Third-party trademarks are property of their respective owners 1 Earliest EU/US/RoW launch year shown 2 Out-licensed molecule
Page 53
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202653 Fresenius Kabi: Global biosimilars pipeline Molecules approved / in registration / clinical/ process validation Status Therapy Area Reference Product (Molecule) Originator Peak Sales (€bn)2 Loss of Exclusivity3 Potential Revenue Contribution Approved (US) Oncology MabThera®/Rituxan® (rituximab) 7 US: Expired, EU: Expired Regulatory Decision Ophthalmology Eylea® (aflibercept) 10 US: Expired EU: Expired Regulatory Decision Gastroenterology Entyvio® (vedolizumab) 6 US: 2027-2032 EU: 2027-2032 Phase III Immunology Enbrel® (etanercept)1 3 US: 2029 EU: Expired Phase I Oncology Opdivo® (nivolumab)1 10 US: 2028 EU: 2030 Note: Third-party trademarks are property of their respective owners | Originator peak sales and LoE dates based on internal analysis from multiple subscription databases 1 Out-licensed molecule | 2 Peak sales are based on originator list-price-based sales and loss of exclusivity (data on file) | 3 Loss of exclusivity (LOE) dates are sourced from: IPD Analytics, www.ipdanalytics.com, (last accessed October 19, 2026), and should not be interpreted as reflecting Fresenius’ internal legal analysis, position, or assessment Limited Moderate High
Page 54
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202654 Fresenius Kabi: Global biosimilars pipeline Disclosed molecules in early-stage development Therapy Area Reference Product (Molecule) Originator Peak Sales (€bn)1 Loss of Exclusivity2 Immunology Skyrizi® (risankizumab) 28 US: 2034-2036, EU: 2034-2036 Immunology Dupixent® (dupilumab) 25 US: 2031-2034, EU: 2033 Immunology Tremfya® (guselkumab) 12 US: 2031, EU: 2032 Oncology Imfinzi® (durvalumab) 9 US: 2031, EU: 2034 Immunology Cosentyx® (secukinumab) 7 US: 2029, EU: 2030 Hematology Hemlibra® (emicizumab)2 6 US: 2032-2038, EU: 2033 Oncology Polivy® (polatuzumab vedotin) 3 US: 2033, EU: 2036 Ophthalmology Tepezza® (teprotumumab) 2 US: 2039, EU: 2035 Note: Third-party trademarks are property of their respective owners | Originator peak sales and LoE dates based on internal analysis from multiple subscription databases 1 Peak sales are based on originator list-price-based sales and loss of exclusivity (data on file) | 2 Loss of exclusivity (LOE) dates are sourced from: IPD Analytics, www.ipdanalytics.com, (last accessed October 19, 2026), and should not be interpreted as reflecting Fresenius’ internal legal analysis, position, o r assessment
Page 55
Fresenius Helios Q3/26 Key financials All figures before special items 1 Organic growth For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202655 ΔYoY cc€m Q3/26 Total revenue 3,405 5%1 Thereof Helios Germany 2,099 5%1 Thereof Helios Spain 1,307 5%1 Total EBIT 293 19% Margin 8.6% +110 bps Thereof Helios Germany 202 25% Margin 9.6% +160 bps Thereof Helios Spain 92 10% Margin 7.0% +40 bps Thereof Corporate -1 --
Page 56
Fresenius Helios Q1-3/26 Key financials All figures before special items 1 Organic growth For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https:/ /www.fresenius.com/financial-results © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202656 ΔYoY cc€m Q1-3/26 Total revenue 10,433 5%1 Thereof Helios Germany 6,287 5%1 Thereof Helios Spain 4,146 4%1 Total EBIT 1,034 13% Margin 9.9% +80 bps Thereof Helios Germany 548 17% Margin 8.7% +100 bps Thereof Helios Spain 486 8% Margin 11.7% +40 bps Thereof Corporate 0 --
Page 57
Fresenius Helios Q1-3/26 Key metrics 1 Helios Germany: adjusted for the impact of hospital and medical center divestments €m Q3/26 Q3/25 ΔYoY Q1-3/26 Q1-3/25 ΔYoY Helios Germany Hospitals 80 84 -5% 80 84 -5% Thereof acute care hospitals 77 81 -5% 77 81 -5% Beds 30,060 29,804 1% 30,060 29,804 1% Thereof acute care hospitals 29,540 29,238 1% 29,540 29,238 1% Admissions1 1,300,484 1,257,173 3% 3,982,914 3,941,960 1% Thereof patients treated in hospital 306,994 299,591 4% 925,977 890,541 4% Thereof patients treated as outpatient 993,490 957,582 4% 3,056,937 3,051,419 0% Helios Spain (incl. Latin America) Hospitals 57 57 0% 57 57 0% Beds 8,389 8,112 3% 8,389 8,112 3% Admissions 5,136,245 4,771,167 8% 16,504,641 15,739,783 5% Thereof patients treated in hospital 252,957 255,466 -1% 882,295 872,546 1% Thereof patients treated as outpatient 4,883,288 4,515,701 8% 15,622,346 14,867,237 5% © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202657
Page 58
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Helios Germany Constructive framework for continued reimbursement growth 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2.52.5 3.0 2.5 3.0 2.7 3.7 2.3 3.5 5.1 4.4 3.0 Inflation in Germany DRG Inflator in % ’20 ’21 ’22 ’23 ’24 ‘25 ‘26 ’27 Increased federal base rate3 Surcharges4 Energy relief funding Hospital Future Act COVID-related compensation DRG Inflator Annual price increase for reimbursement of hospital treatments New methodology for determination1: DRG Inflator equals to the base wage rate2, minus 1% deduction from 2027 to 2029 2027 DRG inflator at 4.85%, i.e. significantly higher than the long- term average Source: German Federal Statistical Office, Annual reports; DRG inflator rounded 1 Based on GKV Stabilization Act, in effect since July 2026 2 Growth rate of health insurance revenues Regular support from additional funds Around 70% of German hospitals are loss-making amid continued cost pressure, requiring additional government support Government support funding in FY/27: • 1.14% federal base rate increase3 • Sector-wide €450m surcharge (expected in 2027) 3 Base for DRG Inflator increase on Federal State level in 2026 for 2027 4 Nov 2025 to 31 Oct 2026: 3.25% surcharge on invoices for publicly insured patients; In 2027: Sector-wide billing surcharge was agreed as part of GKV Stabilization Act protocol declaration 58
Page 59
© Fresenius 2026 | Q3 2026 Earnings Call | 4 November 2026 Helios Germany Regulatory changes playing to our strengths Structural hospital reform1 Create a more quality-driven and specialized hospital sector – in effect since January 2025 with multi-year, phased implementation KHVVG2 (2025) • Introduction of service groups with minimum requirements for staffing, equipment, and expertise to ensure complex treatments are provided by appropriately specialized hospitals • Hospital financing through a combination of DRG-based reimbursement and prefinancing payments to reduce incentives for volume-driven care KHAG3 (Amendments to KHVVG, March 2026) • Service groups: More flexibility in assigning service groups (Federal States) and fulfilling quality criteria • Prefinancing payments: (Partial) implementation postponed to 2028; full effect not until 2030 • Nursing Budget: Specification of scope GKV Stabilization Act1,4 Stabilize the statutory health insurance system (GKV) and limit rising contribution rates – in effect since July 2026 with reimbursement provisions to take effect in 2027 • DRG inflator-based reimbursement increase preserved: Annual DRG inflator to equal the base wage rate (i.e., the growth rate of health insurance revenues) from 2027 to 2029 • Base-wage rate deduction: 1% deduction to the base wage rate from 2027 to 2029 given base wage rate expected significantly higher than long-term average • Refinancing of collective wage increases preserved: Covered at 100% up to the base wage rate and at 50% above the base wage rate • Reimbursement of non-patient related nursing activities: Reductions in 2027 and 2028, ending completely in 2029 • Greater operational flexibility: In allocating nursing staff 1 Selected relevant provisions 2 Krankenhausversorgungsverbesserungsgesetz (“Hospital Care Improvement Act”) 3 Krankenhausreformanpassungsgesetz (“Hospital Reform Adjustment Act”) 4 Act to Stabilize Contribution Rates in the Statutory Health Insurance System (GKV) 59
Page 60
Linkedin www.linkedin.com/company/fresenius-investor-relations Financial Calendar & Contact Financial Calendar Please note that these dates could be subject to change. 10 Dec 2026 Meet the Management Nutrition (virtual) 24 Feb 2027 FY 2026 results 05 May 2027 Q1 2027 results 04 Aug 2027 Q2 2027 results 03 Nov 2027 Q3 2027 results Events You can find a current overview of all upcoming roadshows, conferences, and other capital markets events on the Fresenius Investor Relations website. Investor Feedback and Social Media Open dialogues are vital to us! We have teamed up with Quantifire for quick and convenient feedback sharing. You can submit your feedback anonymously or with attribution by clicking here: Investor & Analyst Feedback Contact Investor Relations Fresenius SE & Co. KGaA Phone:+49 6172 608-97033 E-mail: ir-fre@fresenius.com © Fresenius 2026 | Q3 2026 Earnings Call | 4 November 202660